Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

AALL1631 International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones

Principal Investigator: Twist, Clare J

AGCT1531 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Principal Investigator: Twist, Clare J

(A151216) Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Principal Investigator: Dy, Grace K

A Phase II Trial of Lamivudine in Combination with Chemoimmunotherapy in Patients with Extensive Stage SCLC

Principal Investigator: Dy, Grace K

Phase I/ II Study of Pulmonary Suffusion to Control Minimal Residual Disease in
Resectable or Ablatable Sarcoma or Colorectal Pulmonary Metastases

Principal Investigator: Demmy, Todd L

A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next…

Principal Investigator: Buxbaum, Nataliya P

(A011801) The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with…

Principal Investigator: Levine, Ellis G

A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 with Atezolizumab in Patients with Advanced Cancers Associated with Expression of Delta-like…

Principal Investigator: Jain, Prantesh

EXPANDED ACCESS PROTOCOL (EAP) FOR PATIENTS RECEIVING LISOCABTAGENE MARALEUCEL THAT IS NONCONFORMING FOR COMMERCIAL RELEASE (JCAR017-EAP-001)

Principal Investigator: Ross, Maureen

A Phase 0 Study of CIMAvax-EGF vaccine in Patients Who Are At High Risk for Lung Cancer and Lung Cancer Survivors at Risk for Recurrence

Principal Investigator: Reid, Mary E

(AREN1921) Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Principal Investigator: Twist, Clare J

Propranolol with Standard Chemoradiation for Esophageal Adenocarcinoma - A Combined Single Arm and Randomized Cohort Phase II Study

Principal Investigator: Singh, Anurag K

A Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic…

Principal Investigator: Griffiths, Elizabeth A

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Principal Investigator: Yau, Edwin H

A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

Principal Investigator: Mukherjee, Sarbajit

(S2001) Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations

Principal Investigator: Fountzilas, Christos